Q3 Earnings Forecast for LMAT Issued By Barrington Research

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Equities research analysts at Barrington Research increased their Q3 2025 earnings per share (EPS) estimates for shares of LeMaitre Vascular in a report issued on Friday, February 28th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will earn $0.57 per share for the quarter, up from their previous forecast of $0.55. Barrington Research currently has a "Market Perform" rating on the stock. The consensus estimate for LeMaitre Vascular's current full-year earnings is $1.94 per share. Barrington Research also issued estimates for LeMaitre Vascular's Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.60 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.68 EPS and FY2026 earnings at $2.62 EPS.

A number of other equities analysts have also commented on LMAT. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective on the stock. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday. Finally, StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Stock Up 0.3 %

LMAT traded up $0.31 during midday trading on Monday, hitting $92.16. 299,488 shares of the company were exchanged, compared to its average volume of 137,430. The firm's 50 day moving average price is $96.89 and its 200-day moving average price is $94.90. LeMaitre Vascular has a 1-year low of $62.39 and a 1-year high of $109.58. The firm has a market capitalization of $2.07 billion, a P/E ratio of 50.36, a P/E/G ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $55.81 million during the quarter, compared to analysts' expectations of $55.99 million.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be paid a $0.20 dividend. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Thursday, March 13th. LeMaitre Vascular's payout ratio is 41.24%.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently made changes to their positions in the stock. Copeland Capital Management LLC raised its stake in LeMaitre Vascular by 0.7% during the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock worth $107,990,000 after buying an additional 8,623 shares during the period. State Street Corp grew its position in LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock valued at $76,363,000 after purchasing an additional 28,525 shares during the period. Congress Asset Management Co. grew its position in LeMaitre Vascular by 1.8% in the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock valued at $66,555,000 after purchasing an additional 13,009 shares during the period. Geode Capital Management LLC increased its stake in LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after purchasing an additional 7,737 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in LeMaitre Vascular by 5.1% during the fourth quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock worth $30,205,000 after buying an additional 15,843 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.